Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Research and Development Cost	$ 535,147	$ 355,905	$ 355,905
Cash and cash equivalents	7,936,161		10,445,404
Revenues from sale of treatability services	19,182	8,000
Revenues from sales	296,096	$ 793,458
Inventory allowance	50,000		0
Contract loss provision	$ 600,000		$ 500,000
Share based description	cumulative adjustment of approximately $55,000 in the quarter ended December 31, 2023 to reduce our forfeiture rate estimate to approximately 5% of the total stock-based compensation recognized during the year
Warrants [Member]
Antidilutive Excluded from Computation of Earnings Per Share, Amount	1,235,000	1,250,000
Options [Member]
Antidilutive Excluded from Computation of Earnings Per Share, Amount	10,740,250	13,025,000
One Customer [Member] | Revenue [Member]
Concentrations of Credit Risk	94.00%		99.00%